Showing 1 - 10 of 99
After several years of delays the Personal Data Protection Act B.E. 2562 (2019) ("PDPA") came into force in Thailand on 1 June 2022. Since then, on 20 June 2022, subordinate legislation (the "Notifications") under the PDPA was issued by the Personal Data Protection Committee ("PDPC") and published in the Royal Thai Government Gazette.
These Notifications are intended to set out the various criteria and rules, as well as much needed guidance and clarification, of some key requirements under the PDPA.
Today we announced the launch of our in-depth report, 'Rewriting the risk: Addressing the challenges of climate change', which finds that the underwriting practices of (re)insurers are a major catalyst for change among businesses in the ongoing climate crisis.
As AI continues to gain considerable momentum across the life sciences sector, companies must take steps to understand how AI technologies operate and the risks that they present, the extent to which AI can transform and add value to their business, and implement a framework to provide for its effective incorporation into the organisation.
We have reported our highest ever revenue of £286m, up 8% from £264m* the previous year. The most significant growth came in North America, where revenue was up 24% to £55m, following a continued growth period fed by work from new and existing clients, a series of lateral hires and the opening of a new office in Delaware.
Artificial intelligence in life sciences: regulating AI technologies and the product liability implications
There has been some form of regulation of AI technologies in many life sciences uses in the EU and UK for several years. The EU’s lead on AI regulation began within the medical devices sphere with the introduction of the Medical Device Regulations and In Vitro Diagnostic Regulations (IVDR) (2017/745 and 746) that, belatedly, came into force on 26 May 2021.
In this report, Kennedys experts highlight recent legal and regulatory developments in the product safety and product liability sphere, and provide an overview of the key topics and trends that are likely to impact upon corporates and their insurers in the months ahead.
While artificial intelligence (AI) technologies bring tremendous benefits and opportunities to life sciences businesses, the threats associated with such technologies are wide ranging and complex. This can be exacerbated if companies move too quickly to adopt such sophisticated systems without implementing appropriate securities to protect them.
Kennedys receives top tier rankings in the latest guide to leading law firms and lawyers across the region.
Two years into the pandemic, we consider its impact on the life science sector and how the risk landscape is evolving as the industry builds on the progress it has made.
Artificial intelligence (AI) has transformed the life sciences industry in ways that we could never have imagined. It now impacts each stage of a life science product’s lifecycle — from research and drug discovery to clinical trials, manufacturing, supply chain logistics, marketing, and sales.